TITLE:
Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial

CONDITION:
Breast Cancer

INTERVENTION:
Paclitaxel

SUMMARY:

      The purposes of this are:

        -  To determine the highest doses of Taxol and Navelbine that we can safely give to
           patients;

        -  To determine what kind of side effects are caused by the combination of Taxol,
           Navelbine and G-CSF;

        -  To determine whether the combination of Taxol, Navelbine and G-CSF is more effective
           than standard therapy in treating metastatic breast cancer and prolonging life;
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        INCLUSION

        To be eligible, volunteers must:

          -  Have stage IV carcinoma of the breast that has been microscopically confirmed

          -  Be age > 18

          -  Be fully active or ambulatory with symptoms but able to do light work

          -  Have a life expectancy of > 16 weeks

          -  Be > 2 weeks from prior surgery; > 3 weeks from radiation therapy to the pelvis,
             spine or long bones; > 3 weeks from prior chemotherapy (> 6 weeks for mitomycin C or
             nitrosureas) and > 2 weeks from prior hormonal therapy

          -  Have had one or less prior regimens for metastatic disease

          -  Have measurable (bidimensionally) or evaluable disease that is in an area that has
             not been radiated

        EXCLUSION

        Patients are not eligible if they:

          -  Have rapidly progressing liver or lung metastases or uncontrolled central nervous
             system metastases

          -  Are medically unstable

          -  Are pregnant, nursing or unwilling to employ adequate contraception

          -  Have pre-existing clinically significant peripheral neuropathy except for
             abnormalities due to cancer

          -  Have psychological, familial, sociological or geographical conditions that do not
             permit weekly medical follow-up and compliance with the study protocol

          -  Have hypersensitivity to E. Coli-derived proteins, Filgrastim, or any of its
             components

          -  Have had prior therapy with Navelbine
      
